Project Grant R01AI186027
Award Date
6/6/25
Completion Date
5/31/30
Dollars Obligated
$594K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on optimizing the regimen structure and pharmacokinetic/pharmacodynamic (PK/PD) properties of a five-phage cocktail to treat extensively-drug resistant Pseudomonas aeruginosa (XDR-PA) infections. The $714,053 award, spanning August 2024 to July 2029, aims to: 1) develop quantification assays for the phage cocktail,...
This $299,163 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop a novel antimicrobial approach combining endolysin proteins with self-replicating mRNA (RepRNA) delivery using lipid nanoparticles. The Phase I proof-of-concept study has two key objectives: 1) to evaluate whether RepRNA can successfully express a lysin targeting vancomycin-resistant Enterococcus...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $749,417 to support research focused on developing novel bactericidal antibiotics to address the growing problem of multi-drug resistant pathogens. The research team at Harvard University aims to synthesize and evaluate new antibiotic candidates that target the lipoprotein transport pathway in Gram-negative...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $392,634 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Wisconsin-Madison. The grant supports the development of a novel "nanoimmunotherapeutic" approach to combat multidrug-resistant bacterial infections, particularly the ESKAPE pathogens. Key objectives include designing, fabricating, and optimizing a red blood cell membrane-coated,...
This $256,922 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) aims to develop an adaptive framework to rapidly synthesize and reconfigure synthetic bacteriophages (phages) to counter antibiotic-resistant pathogens. The key products and services to be delivered under this 1-year award include: 1) optimizing an E. coli cell-free...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $474,363 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Rowan University for the "Development of Novel, Daptomycin-Inspired Antimicrobial Peptides Using Non-Canonical Amino Acids". The goal of this project is to develop new antimicrobial peptides based on the clinically approved drug daptomycin, aiming to improve resistance to degradation and optimize synthesis...
This $837,644 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop an effective vaccine targeting poly-b-(1-6)-N-acetylglucosamine (PNAG), a key virulence factor present on many non-viral pathogens. The research team will establish new methodologies to synthesize a comprehensive library of PNAG glycans with varied amine/acetylation patterns, covalently...
This federal Project Grant award, totaling $299,995, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to develop a novel class of membrane-modifying antimicrobials, called Anti-Infective Conjugated Electrolytes (ACEs), to combat critical Gram-negative bacterial pathogens and antimicrobial resistance. The key products to be delivered include: Synthesizing and evaluating ~80...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will develop a novel assay for receptor-guided discovery of environmental bacteriophages (phages). The $173,030 award will be used to create a generalizable co-culture assay that can preferentially select phages requiring specific bacterial membrane proteins or structures for infection. This technique will enable researchers to...
This Project Grant award, valued at $112,077.00 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of novel bacteriophage-based and antimicrobial peptide-based therapies to combat dual-species biofilms formed by the opportunistic pathogens Pseudomonas aeruginosa and Candida species. The research aims to engineer P. aeruginosa-targeting bacteriophages to produce...